Novartis Ups Forecast on Lack of Diovan Competitor

July 17 (Bloomberg) -- Novartis AG raised its full-year forecast as generic competition for the Diovan blood-pressure drug failed to materialize in the U.S. Sam Fazeli reports on Bloomberg Television's "Countdown." (Source: Bloomberg)

Longview's Watling Says Trump Not a Factor for Markets
41:35 - Chris Watling, chief executive officer and chief market strategist at Longview Economics, and Jason Schenker, president and chief economist at Prestige Economics, examine the market influence of President Donald Trump. They speak on "Bloomberg Daybreak: Americas." (Source: Bloomberg)
  • ECB's Draghi Concerned By U.S. Protectionism
  • Citi's Levkovich Is Bullish on Financials and Energy
  • Citigroup's Levkovich Calls Market Sentiment 'Crud'